Introduction
Levetiracetam is thought to have broad-spectrum efficacy, and because it lacks significant pharmacodynamics interactions with other antiepileptic drugs, levetiracetam is an attractive choice for the treatment of seizures associated with childhood epileptic disorders [1, 2] .
In recent years, open-label studies that have examined the use of levetiracetam as an adjunctive therapy in pediatric populations have reported response rates (a reduction in seizure frequency of at least 50%) ranging from 20 to 60% [3] [4] [5] [6] [7] [8] [9] . Levetiracetam monotherapy was well tolerated in these studies, and few adverse events were reported. Although levetiracetam has demonstrated efficacy as adjunctive therapy in children with epileptic disorders, limited data have been reported regarding its use as monotherapy [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Additional clinical studies are needed identify the optimal dosage and to define the efficacy, tolerability and safety of levetiracetam as a monotherapy and its effects on specific epilepsy syndromes.
In the present study, we retrospectively evaluated the efficacy, tolerability and safety of levetiracetam therapy in a large cohort of children (6mo to 18y) with epileptic disorders.
Materials and methods
The subjects for this study were retrospectively identified from the medical records of the Children's Hospital of Katip Çelebi University and the private office records of an author (H.T.) via ICD-9 code searches (345.x seizure). The study population comprised a consecutive series of 351 children who were treated with levetiracetam between 2005 and 2015 and for whom 12 months of clinical follow-up data were available. The demographic, clinical, electroencephalographic (EEG) and magnetic resonance imaging (MRI) findings were recorded. Patient diaries and detailed histories were used to calculate the seizure frequencies as accurately as possible.
The seizure types, etiologies and epileptic syndromes were classified according to the International League Against Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes [2] . The patients were clinically evaluated at 3, 6 and 12months. Electroencephalographic features were evaluated at pretreatment and at 6-12 months during the post-treatment period. An EEG improvement was defined by a pre-treatment EEG that was abnormal and a second EEG that was normal (no spikes or abnormalities). The initial dose of 10 mg/kg/day was increased in 2-week steps of 10 mg/kg/day when necessary up to the maximum dose of 110 mg/kg/day. The blood levels of drug were not collected from the patients. The retention rates for the levetiracetam treatment were recorded for the cohort and the monotherapy group. The clinical responses were graded as complete or partial responses at the 3rd and 12th months of treatment. Complete responses were defined by seizure frequency reductions of 90% or more, and partial-responses were defined by seizure frequency reductions ranging from 50 to 90%. The tolerability and adverse events were assessed by documenting the adverse events that were spontaneously reported by the parents or the children. In the presence of formal psychological tests, the degree of intelligence was defined according to intelligence quotient (IQ) test results. In the absence of formal tests, based on the available information, the degree of cognitive deterioration or improvement was defined according to the clinical judgment of the authors (HT, PG, and NOD).
The database was created and analyzed using SPSS statistical software (version 15.0; Chicago, IL, USA) for Windows. Frequencies and percentages were used to summarize the categorical data, and the continuous data were summarized using the mean and standard deviation (SD) or the median and interquartile range (IQR, Q 75 -Q 25 Table 1) A total of 351 children (210 boys and 141 girls) were enrolled in this study. The median patient age was 9.88 years (IQR, 10.12 years; range, 6 months to 18 years, 25% = 4.51 and 75% = 14.61). A total of 165 patients (47%) had idiopathic epilepsy, and 186 (53%) had symptomatic-cryptogenic epilepsy. In total, 204 (58%) patients had generalized type seizures, and 147 (42%) patients had partial seizures. The majority of the patients (n = 331, 94%) had undergone magnetic resonance imaging (MRI), and 139 (42%) of the images revealed abnormal results that included encephalomalacia (n = 53), cortical dysplasia (n = 27), pachygyria (n = 1), polymicrogyria (n = 1), periventricular leukomalacia (n = 22), cerebral atrophy (n = 17), delayed myelination (n = 10), leukodystrophy (n = 6), mesial temporal sclerosis (n = 1) and a dysembryoplastic neuroepithelial tumor (n = 1). The possible underlying causes of epilepsy were determined in 148 (42%) patients. Forty-seven (32%) patients had hypoxic ischemic encephalopathy, 29 (26%) patients had neurometabolic disorders (e.g., neuronal ceroid lipofuscinosis), 29 (20%) patients had neurodevelopmental disorders (e.g., cortical dysplasia), 22 (15%) patients had prematurity, seven (5%) patients had genetic disorders (e.g., Angelman syndrome, tuberous sclerosis), seven (5%) patients had histories of central nervous system infections, and seven (5%) patients had posttraumatic epilepsy. Attention deficit hyperactivity disorder (ADHD) was accompanied by epilepsy in 38 (11%) patients, and autistic spectrum disorders were accompanied by epilepsy in 16 (5%) patients. Before the patients were administered levetiracetam, the majority had undergone electroencephalography (n = 343, 98%), and 240 (68%) of the patients exhibited abnormal results. A total of 182 (76%) patients had focal discharges, 34 (14%) patients had generalized discharges, and 24 (10%) patients had multifocal discharges. Second EEGs were performed for 138 (39%) patients, and 65 (47%) patients demonstrated improvement. The mean daily doses of levetiracetam were <30 mg/kg in 141 (40%) patients, 30-50 mg/kg in 161 (46%) patients, 60-80 mg/kg in 40 (11%) patients and > 80 mg/kg in 9 (3%) patients. All patients had undergone clinical psychomotor evaluations, and 228 (65%) of these evaluations were normal. Table 1 3.2. The efficacy of levetiracetam in the 3rd month of treatment (Table 2) Overall, greater than 90% seizure reduction rates were observed in 65% of the patients (n = 229), and 50-90% seizure reduction rates were observed in 14% (n = 48). Levetiracetam was more effective in patients with idiopathic epilepsy, normal intelligence and normal MRI findings, patients without psychiatric disorders, and patients with a mean daily dose of <30 mg/kg/day (p = 0.000, p = 0.000, p = 0.000, p = 0.015, and p = 0.000, respectively). The efficacy of levetiracetam was independent of the seizure semiology, gender, and age.
Results

Patients characteristics (
3.3. The efficacy of levetiracetam in the 12th month of treatment (Table 2) Overall, greater than 90% seizure reduction rates were observed in 63% of the patients (n = 129), and 50-90% seizure reduction rates were observed in 15% (n = 30). Similar to the findings at the 3rd month, levetiracetam was more effective in patients with idiopathic epilepsy, normal intelligence and normal MRI findings, patients without psychiatric disorders, and those with a daily mean dose of <30 mg/kg/day as in the 3rd month (p = 0.000, p = 0.000, p = 0.001, p = 0.007, and p = 0.000, respectively). The efficacies of levetiracetam were similar at the 3rd and 12th months of treatment (Fig. 1). 3.4. EEG improvement rates in the period between the 6th and 12th months of treatment (Table 2) EEG improvements (i.e., normal EEGs) were identified in 65 (47%) patients. Significant differences were observed for the patients with idiopathic epilepsy, patients with normal intelligence, normal MRI findings, and a dose of <30 mg/kg/day (p = 0.005, p = 0.006, p = 0.001, and p = 0.008, respectively). We observed no relationships between the rate of EEG improvement and seizure semiology, gender, or age.
Tolerability of levetiracetam and adverse events
The retention rate for the levetiracetam treatment is illustrated in Fig. 2 . All patients were still receiving the levetiracetam treatment at the 3rd month, three-quarters of the patients (n = 262, 75%) were still receiving the levetiracetam treatment at the 6th month, and approximately half of the patients (n = 200, 57%) were still receiving the levetiracetam treatment at the 12th month. The type of epilepsy was not related to discontinuation (p = 0.390). The patients with partial seizures and abnormal MRI findings were more likely to exhibit retention durations of greater than 12 months (p = 0.009 and 0.032, respectively). Overall, 61 (17%) of the patients experienced adverse events (Table 3) . Thirty-three (56%) of these patients were receiving monotherapy, and 24 (44%) were receiving polytherapy. In the monotherapy group, significant differences in terms of seizure semiology, the presence of psychiatric disorder and abnormalities on the pretreatment EEG findings were observed. In the polytherapy group, a significant difference in gender was observed in addition to the differences mentioned above.
The most frequently reported adverse events were irritability (41patients, 67%), hyperactivity (5, 8%), somnolence (4,6%), behavioral disorders (3, 5%), restlessness (3, 5%), increased seizure frequency (2, 3%), enuresis (1, 2%), headache (1, 2%) and attempted suicide (1, 2%). Urine analyses and urine culture for the patient with enuresis were normal, and this patient had no history of neurogenic bladder. Therefore, a urinary tract infection was ruled out. The adverse event rate was independent of age, daily mean dose, MRI abnormalities, mental status and levetiracetam retention time. We found that adverse events were more likely to occur in patients who had experienced partial type seizures and psychiatric disorders and those who exhibited abnormal EEG findings (p = 0.003, p = 0.001 and p = 0.021, respectively). The most important factors were the presence of a psychiatric disorder (OR: 1.8; p: 0.001; 95% CI: 1.3-2.7) and abnormality on the pretreatment EEG (OR: 2.1; p: 0.034; 95%CI: 1.0-4.4). In the monotherapy group, the most important factor was the presence of an abnormality on the pre-treatment EEG (p: 0.045; OR: 2.35; 95% CI: 1.01-5.44). There were no significant differences in the adverse events between the monotherapy and polytherapy groups (p = 0.375; Table 4 ).
Discussion
Levetiracetam has been reported to be a broad-spectrum antiepileptic drug with a safe profile. The data of the present study confirmed the effectiveness of levetiracetam, which was also found to be tolerable and safe as a monotherapy for both partial and generalized epilepsy in childhood at any age. We found that as a monotherapy, levetiracetam reduced the occurrence of seizures by more than 90% in 65% of the patients at the 3rd month of treatment and in 63% of patients at the 12th month of treatment. Currently, there are limited data regarding the use of levetiracetam as a monotherapy in pediatric populations. Weijenberg et al. [3] recently published a systematic review that included 32 studies. These authors concluded that the data concerning levetiracetam monotherapy in children are insufficient to confirm that levetiracetam is effective as an initial monotherapy for different types of seizures and/or epilepsy syndromes. There are currently six published retrospective studies in the literature concerning patients with focal or generalized epilepsy [4] [5] [6] [7] [8] [9] . The first report was that of Koukkari et al. [4] . These authors retrospectively reviewed the charts of 19 consecutive 8-month-oldto 16-year-old patients who were treated only with levetiracetam and reported that the efficacy of levetiracetam was 58%. Khurana et al. [5] also reported efficacy results similar to those of our study. In the present study200 patients (57%) were still receiving the levetiracetam treatment at the end of the 12-month follow-up period (Fig. 2) . The one-year levetiracetam retention rate was reported to be approximately 72.0% in the EULEVp cohort study [22] . Bootsma et al. [23] reported a continuation rate of 65.6% after 1 year. Feng at al. [24] reported levetiracetam retention rates at 6, 12, 24, and 36 months of 93.5% (116/124), 84.7% (105/124), 65.3% (81/124), and 58.9% (73/124), respectively. The predominant causes of withdrawal in this cohort were lack of efficacy (62.7%) and serious adverse effects (17.6%).
Our results suggest that levetiracetam-related adverse events were experienced by 17%of the patients, and behavioral adverse events were experienced by 87% of the patients. The data concerning the frequency of levetiracetam-related adverse events are controversial. The most frequently observed adverse events in our study were irritability, hyperactivity, somnolence and mood disorders. Halma et al. [25] published a review of the behavioral side effects of levetiracetam. In total, 89 behavioral side effects were reported by 524 patients in this review. In general, the rate of behavioral problems was 17.1%. Additionally, monotherapy was administered to 116 patients with localization-related or generalized epilepsies. In this subgroup, a total of 25 behavioral side effects, which included behavioral problems in general (19.0%) and irritability (2.6%), were reported in this review. Sheinberg et al. [26] found no correlations of levetiracetam serum levels with clinical efficacy, tolerability or the administered dosage or between serum concentrations and adverse events. Enuresis was observed in one patient within the first three months of treatment in our cohort. Enuresis is not mentioned as a side effect of levetiracetam treatment in the prescriptions, and the percentage of children taking levetiracetam who experience enuresis is unclear. Nevertheless, the Food and Drug Administration (FDA) website reports enuresis in a few children who were taking multiple medications [27] . We found that adverse events were more likely to occur in patients with partial type seizures, psychiatric disorders, abnormal EEG findings, multidrug regimens and no response to levetiracetam. The occurrence of adverse events was also independent of the mean daily dose and the continuation time in our cohort. We found that levetiracetam effectively improved the EEGs of 47% of the children with focal and generalized epilepsy. There are a few case series that have investigated the effects of levetiracetam on EEGs in children with focal or generalized epilepsy. Kanemura et al. [28] reported on the usefulness of levetiracetam in reducing secondary bilateral synchrony on EEG and seizure frequency in children with epileptic disorder. These authors observed a 50 reduction in bilateral synchrony frequency. Aeby et al. [29] reported that levetiracetam has positive effects on the EEGs, behaviors, and cognition of patients with epilepsy and CSWS. In this study, seven of twelve patients (58.3%) exhibited EEG improvements.
There are 10 prospective, open-label studies of levetiracetam monotherapy [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , but these studies included fewer than 40 cases. According to these studies, the rate of achieving seizure-free status on levetiracetam monotherapy is highly variable (20-100%). The majority of these studies reported that the levetiracetam monotherapy reduced the seizure frequency by more than 50% (62-100%in many cases). Four randomized controlled trials have been published to date. Coppola et al. [20] observed no significant differences in a comparison of levetiracetam monotherapy and oxcarbazepine in patients with benign epilepsy with centrotemporal spikes (BECTS). In their small cohort, Rosenow et al. [21] reported no difference in efficacy between levetiracetam and lamotrigine in patients with focal and generalized epilepsy.
Conclusion
To date, the present study utilized the largest cohort in the literature to examine levetiracetam monotherapy in childhood. To the best of our knowledge, levetiracetam can be safely used as a monotherapy for childhood epilepsy independent of the semiology of seizures. However, well-designed trials are still needed to justify the widespread use of levetiracetam monotherapy in children with specific epilepsy syndromes.
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